FDA approves Eli Lilly's Inluriyo (imlunestrant) with Verzenio for ESR1-mutated advanced breast cancer

The US FDA approved Eli Lilly's Inluriyo (imlunestrant) in combination with Verzenio for ESR1-mutated advanced breast cancer, and the product is now available in the US.

Detected & updated continuously · Source: Nebula